Results from the FINESSE trial, reported in the

New England Journal of Medicine
(
2008
;
358
[21]:
2205
–2217)
, show no advantage of early abciximab or a half-dose lytic plus abciximab combination over primary percutaneous coronary intervention alone in patients with ST-segment elevation myocardial infarction. Experts say it is time to focus on improving door-to-balloon times, not on “facilitating” with drugs, and educating the public on symptom recognition.

In April 2008, the Agency for Healthcare Research and Quality (AHRQ) and the Robert Wood Johnson Foundation jointly sponsored the development of Patient Safety and Quality: An Evidence-Based Handbook for Nurses. The purpose of this free resource is to bring quality and safety into focus for nurses working in today’s complex health care environment. This book is divided into 6 sections, each offering peer-reviewed discussion and reviews of...

You do not currently have access to this content.